Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Johnson & Johnson’s teclistamab combination secured a record-breaking 55-day FDA approval under the Commissioner’s National Priority Voucher pilot, setting a new benchmark for accelerated hematology
Manufacturing and regulatory milestones anchor today’s action. Vericel’s FDA approval for its new cell therapy facility positions MACI for international expansion, while Glenmark secures 180-day
Non-dilutive financing is redefining late-stage development economics. Teva’s $400 million Blackstone deal for duvakitug and Royalty Pharma’s APAC expansion signal that asset-specific capital—not balance-sheet debt—is
The FDA drew a hard line on gene therapy Monday, fully liberating Intellia’s CRISPR pipeline from clinical holds while simultaneously enforcing a rigorous Phase 3
Last week was defined by regulatory milestones and market reality checks. The FDA approved Ascendis Pharma’s YUVIWEL (navepegritide) on Friday, the second achondroplasia therapy and
Boehringer Ingelheim’s zongertinib has secured a landmark 44-day FDA approval under the new National Priority Voucher pilot, fundamentally rewriting the timeline for bringing critical drugs
GSK has re-entered the pulmonary arterial hypertension arena with a $950 million acquisition of 35Pharma, positioning itself to directly challenge Merck’s blockbuster Winrevair with a
Novo Nordisk announced it will reduce U.S. list prices of its semaglutide portfolio by up to 50% to a uniform $675 per month effective January
Gilead Sciences has ignited the 2026 M&A cycle with a $7.8 billion acquisition of Arcellx at a 79% premium, securing a dominant position in BCMA-directed
The FDA’s single-trial doctrine shifted from proposal to practice last week, while Friday delivered two approvals—Vanda’s Bysanti for bipolar I disorder and schizophrenia, and CStone’s
